Vericel Corporation $VCEL Stock Sold by Summit Creek Advisors LLC

Key Points

• Summit Creek Advisors cut its Vericel stake by 21.6% in the third quarter, selling 47,429 shares and retaining 171,883 shares valued at about $6.9 million.
• Vericel reported quarterly revenue of $85.4 million, up 26.5% year over year, and EPS of $0.27, beating analyst estimates. The company also raised its full-year revenue outlook to $344 million–$346 million.
• Analysts’ consensus rating is Moderate Buy, with an average price target of $60.80; company insiders recently sold a combined 22,000 shares.

Summit Creek Advisors LLC reduced its stake in Vericel Corporation (NASDAQ:VCEL - Free Report) by 21.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 171,883 shares of the biotechnology company's stock after selling 47,429 shares during the period. Vericel comprises approximately 2.8% of Summit Creek Advisors LLC's investment portfolio, making the stock its 6th largest position. Summit Creek Advisors LLC owned 0.34% of Vericel worth $6,899,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in VCEL. MCF Advisors LLC increased its position in Vericel by 293.0% during the 2nd quarter. MCF Advisors LLC now owns 782 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 583 shares in the last quarter. Ameritas Advisory Services LLC bought a new position in Vericel in the 2nd quarter valued at approximately $36,000. Allworth Financial LP acquired a new stake in Vericel in the second quarter valued at approximately $60,000. Integrated Wealth Concepts LLC acquired a new stake in Vericel in the second quarter valued at approximately $72,000. Finally, GAMMA Investing LLC boosted its position in Vericel by 17.7% in the second quarter. GAMMA Investing LLC now owns 1,886 shares of the biotechnology company's stock valued at $84,000 after buying an additional 283 shares in the last quarter.

Analysts Set New Price Targets

VCEL has been the topic of a number of research reports. TD Cowen boosted their target price on shares of Vericel from $55.00 to $58.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Canaccord Genuity Group set a $60.00 price target on Vericel in a research note on Thursday, July 30th. Wall Street Zen raised Vericel from a "buy" rating to a "strong-buy" rating in a report on Saturday. Truist Financial set a $65.00 price objective on Vericel in a report on Friday. Finally, Weiss Ratings restated a "hold (c)" rating on shares of Vericel in a research report on Thursday, October 29th. Four research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, Vericel currently has an average rating of "Moderate Buy" and an average target price of $60.80.

Vericel Price Performance

Vericel stock opened at $54.62 on Friday. The business has a 50 day moving average of $41.01 and a 200-day moving average of $38.90. Vericel Corporation has a 1 year low of $28.95 and a 1 year high of $55.60. The company has a market capitalization of $2.80 billion, a P/E ratio of 85.35 and a beta of 1.08.

Vericel (NASDAQ:VCEL - Get Free Report) last posted its earnings results on Thursday, November 5th. The biotechnology company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.06 by $0.21. Vericel had a net margin of 10.27% and a return on equity of 9.09%. The business had revenue of $85.37 million for the quarter, compared to the consensus estimate of $77.95 million. During the same period last year, the company earned $0.10 EPS. The firm's revenue was up 26.5% compared to the same quarter last year. Equities analysts anticipate that Vericel Corporation will post 0.54 EPS for the current year.

Insider Buying and Selling at Vericel

In other Vericel news, Director Robert Zerbe sold 3,000 shares of the company's stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $52.23, for a total value of $156,690.00. Following the completion of the transaction, the director directly owned 32,995 shares in the company, valued at approximately $1,723,328.85. This represents a 8.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Sean Flynn sold 15,000 shares of the firm's stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $51.92, for a total transaction of $778,800.00. Following the transaction, the insider directly owned 1,990 shares of the company's stock, valued at $103,320.80. The trade was a 88.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 22,000 shares of company stock worth $1,128,340. 7.60% of the stock is currently owned by company insiders.

More Vericel News

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported Q3 revenue of $85.4 million, up 26.5% year over year and above the $78.0 million consensus. Earnings per share of $0.27 also topped estimates of $0.06, while net income rose 179% to $14.2 million. Vericel Q3 results and guidance
• Positive Sentiment: The company raised its FY2026 revenue outlook to $344 million–$346 million, above analyst expectations of roughly $336 million, and lifted its adjusted EBITDA margin guidance to 28%. The stronger outlook, alongside record MACI sales, helped fuel investor optimism. Vericel shares rise on record revenue and higher outlook
• Positive Sentiment: HC Wainwright raised its price target to $75 from $72 and maintained a Buy rating, signaling continued analyst confidence in the stock’s prospects. HC Wainwright price target update
• Negative Sentiment: Several Vericel directors and insiders disclosed stock sales totaling about 22,000 shares on November 4–5. One insider’s sale reduced their reported stake by 88%, which may be a near-term concern for investors, though insider sales alone do not establish a negative outlook. SEC insider transaction filing

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient's own cells or biologic materials to support tissue repair and healing.

Vericel's primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.